Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy

Authors

Jacques E. Rossouw, National Institutes of Health, Bethesda, MD
Karen C. Johnson, University of Tennessee
Mary Pettinger, Fred Hutchinson Cancer Research Center, Seattle, WA
Mary Cushman, University of Vermont
Per M. Sandset, Oslo University
Lewis H. Kuller, University of Pittsburgh
Frits Rosendaal, Leiden University Medical Center
Jan Rosing, Maastricht University
Sylvia Wasserthal-Smoller, Albert Einstein College of Medicine
Lisa W. Martin, George Washington UniversityFollow
Joann E. Manson, Brigham and Women's Hospital, Boston, MA
Kamakshi Lakshminarayan, University of Minnesota
Jose G. Merino, National Institutes of Health, Bethesda, MD
John Lynch, National Institutes of Health, Bethesda, MD

Document Type

Journal Article

Publication Date

4-2012

Journal

Stroke

Volume

43

Issue

4

Inclusive Pages

952-957

DOI

10.1161/STROKEAHA.111.643072

Keywords

Activated Protein C Resistance--blood; Brain Ischemia--blood; Brain Ischemia--epidemiology; Hormone Replacement Therapy; Lipoproteins--blood; Postmenopause--blood; Stroke--blood; Stroke--epidemiology

Comments

This is a PubMed Central article. Click on link for full-text access.

APA Citation

Rossouw, J. E., Johnson, K. C., Pettinger, M., Cushman, M., Sandset, P. M., Kuller, L., . . . Lynch, J. (2012). Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. Stroke, 43(4), 952-957.

Peer Reviewed

1

Open Access

1